RHRobert Hill

Robert Hill

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Robert Hill has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Real‐world experiences of adult individuals or caregivers of children who received teplizumab treatment in stage 2 type 1 diabetes

    by Holly K. O'DOnnell, Kimber M. Simmons, Stephen E. Gitelman, Terry Dex, Robert Hill, Mattias Wieloch, Julia Zaccai, Jennifer D'SOuza, France Ginchereau Sowell, James Turnbull, et al.

    Aims: This study surveyed individuals and caregivers of children who received teplizumab at stage 2 type 1 diabetes (T1D) to garner real‐world experiences and their health outlook for the future following treatment with the first approved disease‐modifying immune therapy for delaying the onset of Stage 3 T1D. Materials and Methods: This was a cross‐sectional, observational, online survey (conducted September–October 2024) of adults (≥18 years) and caregivers of children (8–17 years) who received teplizumab while participating in the US COMPASS patient support program. Questions pertained to demographics, health history, T1D screening, the decision to take teplizumab, treatment, post‐treatment experience, outlook on prognosis and self‐reported health status. All data were summarized using descriptive statistics. Results: A total of 47/116 invited individuals responded (30 adults, 17 caregivers of children). Almost half of respondents had a family history of T1D, and 36% reported autoimmune comorbidities. The top reason for both screening for T1D and receiving teplizumab was for a chance at delaying Stage 3 T1D. Although respondents expressed continued concern over diabetes progression, 87% felt grateful to receive teplizumab, 72% felt it would help slow down the disease, 60% felt it would make T1D easier to manage and most (>80%) would recommend treatment/make the same decision for another family member. Conclusions: Individuals living with or caring for someone who received teplizumab felt grateful for the opportunity to delay disease or make it easier to manage following teplizumab, with most agreeing they would recommend teplizumab and make the same decision for family in their situation. Plain Language Summary: Type 1 diabetes (T1D) happens when the body destroys cells in the pancreas that make insulin. This ultimately causes high blood sugar. People with T1D often worry about the long‐term effects of the disease. Teplizumab is the first FDA‐approved treatment that delays the onset of high blood sugar in people in the early stages of T1D—when there are signs of cell damage and mild increases in blood sugar. We surveyed adults ( N = 30) and caregivers ( N = 17) of children treated with teplizumab about their journey before and after treatment. More than half of adults were initially told they might have a different type of diabetes, usually type 2, before being accurately diagnosed with early‐stage T1D. Doctors specializing in diabetes were most often the ones who recommended screening for T1D. The most common reason to screen was a chance for more time before the onset of high blood sugar. Greater than 80% of people were grateful they or their child had the opportunity to receive teplizumab, and most would recommend it to others in a similar situation. After receiving teplizumab, most people still worried about their blood sugar and measured it frequently. Most thought that teplizumab would delay the disease progression to symptoms, and more than half thought teplizumab would make T1D easier to manage. These findings are the first to describe the journey of adults and caregivers of children treated with teplizumab, their reasons for screening, and their beliefs about the future.


  • Open Access

    The effect of different fluoride varnishes on the release of calcium ions from hydroxyapatite discs: An ion-selective electrodes study

    by Aimi Kamarudin, Paul Anderson, Robert Hill

    Introduction: Recently, various modes of fluoride varnishes have evolved, each with its own recommended concentration, potentially active ingredients, and flavour, leading to a claim of additional preventive benefits. Differences in fluoride release patterns can potentially enhance or reduce the efficacy of fluoride varnishes. Numerous clinical trials have proven its ability in preventing and arresting dental caries. This study mainly focused on the investigations of the apatite demineralisation process under the effect of different fluoride varnishes by ion-selective electrodes (ISE), in an attempt to comprehend their mechanism in anti-caries. Methods: Four different fluoride varnishes (Fluor Protector S, Duraphat, ClinPro White, MI Varnish) were used to measure their effect on the demineralisation process of the hydroxyapatite (HAP) discs in 60ml pH 4.0 acetic solutions. The HAP discs were treated with these varnishes after 4-hours demineralisation and then immersed back into the same solutions for further demineralisation to observe the effect of the varnishes. Throughout the experiment, the calcium ISE was used to monitor the rate of calcium concentration. Results: The result demonstrated that ClinPro White varnish resulted in the most significant inhibition of demineralisation and signs of probable remineralisation throughout the experiment. Other fluoride varnishes treatment showed the ability to inhibit demineralisation. However, the rate of calcium dissolution was not significantly different from different varnishes. The fact that the ClinPro White showed evidence of remineralisation might be associated with the fact that the varnish contained a source of calcium and phosphate. Conclusion: The fluoride varnishes treatment is shown to be effective in inhibiting the demineralisation of apatite regardless of the difference in fluoride concentration and potentially active ingredients incorporated in some of the fluoride varnishes.


  • Open Access

    Continuous hyperfractionated accelerated radiotherapy – Escalated dose (CHART-ED): A phase I study

    by Matthew Quintin Fielding Hatton, Robert Hill, John David Fenwick, Sally A. Morgan, Paula C. Wilson, Philip James Atherton, Jeanette Dickson, Kirsten Eleanor Murray, James Paul


  • Procedure-Specific Surgical Site Infection Rates and Postdischarge Surveillance in Scotland

    by J. Reilly, G. Allardice, J. Bruce, R. Hill, J. McCoubrey

    Objective.: To investigate the impact of postdischarge surveillance (PDS) on surgical-site infection (SSI) rates for selected surgical procedures in acute care hospitals in Scotland.Design.: Prospective surveillance of SSI after selected surgical procedures.Setting.: The Scottish Surveillance of Healthcare Associated Infection Programme (SSHAIP), which is based on the methodology of the Centers for Disease Control and Prevention (CDC) National Nosocomial Infections Surveillance system (NNIS). Thirty-two of 46 acute care hospitals throughout Scotland contributed data to SSHAIP for this study.Methods.: Data were from 21,710 operations that took place between April 1, 2002, and June 30, 2004; nine categories of surgical procedures were analyzed. CDC NNIS system definitions and methods were used for SSI PDS. PDS is a voluntary component of the mandatory SSI surveillance program in Scotland. PDS was categorized as none, passive, active without direct observation, and active with direct observation.Results.: From our study information, PDS data were available for 12,885 operations (59%). A total of 2,793 procedures (13%) were associated with passive PDS and 10,092 (46%) with active PDS. The SSI rate among the 8,825 operations with no PDS was 2.61% (95% confidence interval [CI], 2.3%-3.0%), which was significantly lower than the SSI rate found among the 12,885 operations for which PDS was performed (6.34% [95% CI, 5.9%-6.8%]). For breast surgery, cesarean section, hip replacement, and abdominal hysterectomy, the rate of SSI when PDS was performed was significantly higher than that when PDS was not performed (P< .01 for each procedure). No differences in SSI rates were found for surgery to repair fractured neck of the femur or for knee replacement. SSI rates were examined according to procedure type, performance of PDS, and NNIS risk index; rates of SSI increased with NNIS risk index within procedure group and PDS group. Logistic regression analyses confirmed that procedure type, performance of PDS, and NNIS risk index were all statistically independent predictors of report of an SSI (P< .05).Conclusions.: This Scottish national data set incorporates a substantial amount of PDS data. We recommend a procedure-specific approach to PDS, with direct observation of patients after breast surgery, cesarean section, and hysterectomy, for which the length of stay is typically short. Readmission surveillance may be adequate to detect most SSIs after orthopedic surgery or vascular surgery, for which the length of stay is typically longer.


  • A MAS-NMR and Combined Rietveldt Study of Mixed Calcium/Strontium Fluorapatite Glass-Ceramics

    by Robert G. Hill, Adam Calver, Stephen Skinner, Artemis Stamboulis, Robert V. Law

    Strontium is one of the most common substituents in apatite crystals. The presence and behavior of Sr in apatite-group phases are of considerable significance in biology. The present paper investigates the substitution of strontium for calcium in a glass-ceramic of the following composition 4.5SiO23Al2O31.5P2O54CaO1CaF2. The glasses were characterized using Differential Thermal Analysis (DTA), X-ray powder diffraction (XRD), neutron diffraction (ND) and 19F Resonance Magic Angle Spinning Nuclear Magnetic Resonance (MAS-NMR). The all calcium glass crystallized to calcium fluorapatite (Ca5(PO4)3F). Substituting strontium partially for calcium resulted in the formation of a mixed strontium/calcium fluorapatites. In contrast complete substitution resulted in the formation of strontium fluorapatite. MAS-NMR showed the the F to be present as F-Ca(3) representing a fluoride ion surrounded by three Ca2+ ions in the all calcium glass and was present as F-Sr(3) in the all strontium glass. In the mixed glasses fluorine was present as FCa( 3), F-Ca(2)Sr, F-CaSr(2) and F-Sr(3). Ca had a higher tendency to occupy the F-M(3) sites than Sr which may reflect the higher charge to size ratio of Ca2+ relative to Sr2+ and its greater affinity for F- ions.


  • Open Access

    Surgical site infection after groin hernia repair

    by E W Taylor, K Duffy, K Lee, R Hill, A Noone, I Macintyre, P M King, P J O'Dwyer

    Background: Post-discharge surveillance for 30 days is needed to determine the true incidence of surgical site infection (SSI). This study was undertaken to determine the incidence of, and risk factors for, SSI after hernia repair. Methods: A total of 3150 patients who had undergone groin hernia repair in 32 Scottish hospitals were telephoned 10, 20 and 30 days after operation to screen for SSI. Patients who believed the wound to be infected were seen by a healthcare worker to confirm the diagnosis. Details of operations and risk factors were obtained by case-note review. Results: One hundred and four patients (3·3 per cent) declined to give a contact telephone number, leaving 3046 patients who agreed to take part in the study. Some 108 patients (3·4 per cent) could not be contacted at any point, giving a response rate of 93·3 per cent. Complete data were available for 2665 patients (87·5 per cent); 140 (5·3 per cent) developed SSI and 57 (2·1 per cent) thought the wound infected but this was not confirmed by the healthcare worker. Patients given a prophylactic antibiotic had a lower incidence of SSI (P = 0·002), but neither increase in the American Society of Anesthesiologists grade of fitness for operation nor prolonged duration of operation was a significant risk factor for infection. Conclusion: SSI after hernia repair is common and large clinical trials are required to determine whether the use of prophylactic antibiotics reduces the incidence of infection.


  • Open Access

    Experience of reversal of sterilisation at Glasgow Royal Infirmary

    by Sivaraman Prabha, C Burnett Lunan, Robert Hill

    Objective To review experience at the Glasgow Royal Infirmary with regard to women who underwent reversal of sterilisation, to obtain a profile of these women and to evaluate the procedure itself in terms of safety and restoration of fertility. Design A retrospective study based on case records from the Glasgow Royal Infirmary and from the Glasgow Royal Maternity Hospital, both of which share the same catchment area. Participants Eighty-five women underwent reversal of sterilisation between 1 January 1994 and 31 December 1998 at the Glasgow Royal Infirmary. Follow-up at the Glasgow Royal Maternity identified 43/85 women. Methods Patients were identified from relevant theatre log books and from records at the maternity hospital until December 2000 and their case notes reviewed. Results Having a new partner was responsible for 90% of requests. Median age at request for reversal was 34 years and most had been sterilised before the age of 30 years. There were few postoperative complications. Pregnancy occurred in at least 43% of women. Conclusion Reversal of sterilisation is a safe and effective method of restoring fertility. The actual incidence of pregnancy after reversal is likely to be higher than the 43.5% recorded due to difficulties in achieving 100% follow-up.


  • Surgeon experience and patient comfort during clear corneal phacoemulsification under topical local anesthesia

    by Manu R.K. Mathew, Lennox A. Webb, Robert Hill

    To evaluate patient comfort during topical anesthesia clear corneal phacoemulsification surgery performed by a surgeon in the learning curve or by an experienced surgeon. Royal Alexandra Hospital, Paisley, Scotland, United Kingdom. This study comprised 46 consecutive patients having phacoemulsification under topical anesthesia of proparacaine 0.5% (Proxymetacaine. Surgery was performed by a surgeon during his learning curve (n = 20) or by an experienced surgeon (n = 26). No sedation or intracameral anesthesia was used in either group. All patients had clear corneal phacoemulsification with foldable acrylic posterior chamber intraocular lens implantation. Each patient's subjective experience of overall pain perioperatively (period immediately surrounding and during surgery) and worst pain perceived during surgery was measured immediately after surgery using a 10-point visual analog scale. There was no significant difference in patient-reported pain scores for overall pain perioperatively (P =.47, Wilcoxon rank sum test) and the worst pain perceived during surgery (P =.32, Wilcoxon rank sum test). Topical anesthesia with proparacaine provided similar and reasonable analgesic effects in patients having surgery by a surgeon in the learning curve and those having surgery by an experienced surgeon. The discomfort perceived during surgery performed by an experienced surgeon was less, although not statistically significantly different.


  • Retinopathy of prematurity: are we screening too many babies?

    by M R K Mathew, A I Fern, R Hill

    Purpose With advancement in neonatal care units, early detection of retinopathy of prematurity (ROP) in premature and very-low-birth-weight infants is important. Numerous studies have reported an increased risk of ROP in prematurely born infants, but only few have been long-term and strictly population-based. The aim of the present study was to find out whether birthweight Methods Infants either with a birth weight below 1500 g or a gestational age of less than 32 weeks were screened for ROP during an 8-year period by a single examiner.Results An incidence of 64/205 (31.2%) ROP was noted. The mean age at detection was 5.5 ± 2 weeks of life. The maximum stage reached was stage 1 in 27 (13.2%), stage 2 in 24 (11.7%) and stage 3 in 10 (4.8%) babies. Threshold ROP was present in three (1.5%) babies. Significantly fewer (150/205 = 73%) babies would have been examined had a birth weight of 1250 grams and eight (12%) babies with gestational age >30 weeks amongst babies with ROP but all were stage 1 or stage 2. All the stage 3 ROP and the threshold ROP cases were babies with birth weight Conclusion Ophthalmic examination may be safely and efficiently concentrated in babies with birth weight P < 0.005) and gestational age (P < 0.01) were the only significant risk factors. During this 8-year period there was no significant decrease in the number of babies screened for ROP and the overall incidence of all stages of the disease has remained constant. In the present series a lower incidence of severe ROP was noted compared to most previous studies. Our experience from this study suggests the need for further refinement of screening guidelines in order to focus screening on the vision-threatening stages of ROP.